Redhill Financial Statements From 2010 to 2025

RDHL Stock  USD 1.20  0.11  8.40%   
Redhill Biopharma's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Redhill Biopharma's valuation are provided below:
Gross Profit
4.9 M
Profit Margin
(1.03)
Market Capitalization
2.8 M
Enterprise Value Revenue
1.5313
Revenue
M
There are over one hundred nineteen available trending fundamental ratios for Redhill Biopharma, which can be analyzed over time and compared to other ratios. We recommend to check out Redhill Biopharma's recent fundamental drivers against the all of the trends between 2010 and 2025.

Redhill Biopharma Total Revenue

7.64 Million

Check Redhill Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Redhill Biopharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 588 K, Interest Expense of 504 K or Selling General Administrative of 18.2 M, as well as many indicators such as Price To Sales Ratio of 1.81, Dividend Yield of 0.0 or Days Sales Outstanding of 154. Redhill financial statements analysis is a perfect complement when working with Redhill Biopharma Valuation or Volatility modules.
  
Build AI portfolio with Redhill Stock
Check out the analysis of Redhill Biopharma Correlation against competitors.
For more information on how to buy Redhill Stock please use our How to buy in Redhill Stock guide.

Redhill Biopharma Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets17.1 M18 M63 M
Slightly volatile
Other Current Liabilities19.7 M14 M18 M
Slightly volatile
Total Current Liabilities32.5 M22.2 M29.7 M
Slightly volatile
Other Liabilities2.8 M5.3 MM
Slightly volatile
Accounts Payable8.3 M7.9 M3.8 M
Slightly volatile
Cash4.4 M4.6 M18.8 M
Very volatile
Long Term Debt101 M96.2 M45 M
Slightly volatile
Common Stock Shares Outstanding2.6 M2.5 M381.9 K
Slightly volatile
Short Term Investments863.1 K908.5 K9.8 M
Pretty Stable
Other Current Assets73.2 K77 K2.5 M
Slightly volatile
Total Liabilities21.6 M22.7 M43 M
Slightly volatile
Preferred Stock Total Equity1.6 K1.8 KK
Slightly volatile
Intangible Assets5.3 M5.5 M18.1 M
Slightly volatile
Common Stock36.8 M35 M6.4 M
Slightly volatile
Property Plant Equipment5.1 M4.9 M2.1 M
Slightly volatile
Property Plant And Equipment Net415.1 K437 K1.5 M
Slightly volatile
Non Current Assets Total5.8 M6.1 M21.7 M
Slightly volatile
Other Assets19.5 M18.6 M6.5 M
Slightly volatile
Cash And Short Term Investments4.4 M4.6 M29.1 M
Pretty Stable
Net Receivables3.4 M3.6 M7.3 M
Slightly volatile
Common Stock Total Equity1.3 M1.2 M664.4 K
Slightly volatile
Liabilities And Stockholders Equity17.1 M18 M63.6 M
Slightly volatile
Non Current Liabilities Total477.9 K503 K13.6 M
Pretty Stable
Other Stockholder Equity231.1 M375.1 M200.4 M
Slightly volatile
Property Plant And Equipment Gross2.2 M1.7 M1.9 M
Slightly volatile
Total Current Assets11.3 M11.9 M41.8 M
Pretty Stable
Long Term Investments137 K174.8 K127.2 K
Slightly volatile
Capital Stock36.8 M35 M6.7 M
Slightly volatile
Short and Long Term Debt Total338.2 K356 K21.1 M
Slightly volatile
Current Deferred Revenue0.860.98.4 M
Very volatile
Capital Lease Obligations338.2 K356 K3.6 M
Slightly volatile
Short Term Debt335.4 K353 K8.1 M
Pretty Stable
Short and Long Term Debt92.2 M103.7 M113.1 M
Slightly volatile

Redhill Biopharma Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Interest Expense504 K530.5 K2.2 M
Pretty Stable
Selling General Administrative18.2 M14.5 M16.7 M
Slightly volatile
Other Operating Expenses21.5 M22.7 M43.9 M
Slightly volatile
Research Development1.5 M1.6 M13.2 M
Very volatile
Total Revenue7.6 MM16.2 M
Slightly volatile
Cost Of RevenueM3.2 M14.1 M
Pretty Stable
Selling And Marketing Expenses951.9 KM7.4 M
Slightly volatile
Interest Income168.4 K133 K234.7 K
Slightly volatile
Reconciled Depreciation588 K619 K2.5 M
Slightly volatile

Redhill Biopharma Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation631.8 K665 K2.6 M
Slightly volatile
Begin Period Cash Flow5.3 M5.6 M18.6 M
Pretty Stable
Capital Expenditures8.6 KK3.8 M
Pretty Stable
Total Cash From Financing ActivitiesM8.4 M28.7 M
Pretty Stable
End Period Cash Flow4.4 M4.6 M18.8 M
Very volatile
Depreciation588 K619 K2.5 M
Slightly volatile
Sale Purchase Of Stock34.8 M41.8 M28.1 M
Slightly volatile
Issuance Of Capital Stock7.8 M8.3 M35.6 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio1.811.90297.9 K
Pretty Stable
Days Sales Outstanding154162K
Pretty Stable
Stock Based Compensation To Revenue0.07850.082758.2321
Slightly volatile
Capex To Depreciation0.01380.01459.2884
Slightly volatile
EV To Sales18.1 K19 K79.3 M
Pretty Stable
Payables Turnover0.390.406149.5302
Pretty Stable
Sales General And Administrative To Revenue1.711.804745.2793
Slightly volatile
Research And Ddevelopement To Revenue0.190.1974442
Pretty Stable
Capex To Revenue0.00110.001136.7716
Pretty Stable
Cash Per Share1.781.87341.1 K
Slightly volatile
Days Payables Outstanding944899280
Slightly volatile
Intangibles To Total Assets0.160.30740.1858
Slightly volatile
Current Ratio0.510.5369.5921
Slightly volatile
Receivables Turnover1.882.25552.5132
Very volatile
Capex Per Share0.00350.003767.2409
Very volatile
Average Receivables3.3 M3.4 M18.4 M
Slightly volatile
Revenue Per Share3.13.2635196
Slightly volatile
Interest Debt Per Share0.340.3597233
Slightly volatile
Debt To Assets0.01870.01970.1465
Slightly volatile
Graham Number0.00520.00580.0063
Slightly volatile
Days Of Payables Outstanding944899280
Slightly volatile
Ebt Per Ebit0.540.56581.1506
Pretty Stable
Long Term Debt To Capitalization0.70.810.8513
Pretty Stable
Quick Ratio0.350.371710.8709
Slightly volatile
Net Income Per E B T0.80.90.9799
Slightly volatile
Cash Ratio0.20.20786.3255
Slightly volatile
Days Of Sales Outstanding154162K
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio1.251.0011.1466
Very volatile
Fixed Asset Turnover10.4918.40512.1397
Pretty Stable
Debt Ratio0.01870.01970.1465
Slightly volatile
Price Sales Ratio1.811.90297.9 K
Pretty Stable
Asset Turnover0.470.44580.1847
Slightly volatile

Redhill Fundamental Market Drivers

Forward Price Earnings1428.5714
Cash And Short Term Investments4.6 M

Redhill Upcoming Events

26th of April 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View

About Redhill Biopharma Financial Statements

Redhill Biopharma investors utilize fundamental indicators, such as revenue or net income, to predict how Redhill Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue 0.90  0.86 
Total RevenueM7.6 M
Cost Of Revenue3.2 MM
Stock Based Compensation To Revenue 0.08  0.08 
Sales General And Administrative To Revenue 1.80  1.71 
Research And Ddevelopement To Revenue 0.20  0.19 
Revenue Per Share 3.26  3.10 
Ebit Per Revenue(1.82)(1.91)

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Prophet
When determining whether Redhill Biopharma is a strong investment it is important to analyze Redhill Biopharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Redhill Biopharma's future performance. For an informed investment choice regarding Redhill Stock, refer to the following important reports:
Check out the analysis of Redhill Biopharma Correlation against competitors.
For more information on how to buy Redhill Stock please use our How to buy in Redhill Stock guide.
You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Redhill Biopharma. If investors know Redhill will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Redhill Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Revenue Per Share
6.527
Quarterly Revenue Growth
3.82
Return On Assets
(0.37)
Return On Equity
(17.09)
The market value of Redhill Biopharma is measured differently than its book value, which is the value of Redhill that is recorded on the company's balance sheet. Investors also form their own opinion of Redhill Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Redhill Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Redhill Biopharma's market value can be influenced by many factors that don't directly affect Redhill Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Redhill Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Redhill Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Redhill Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.